Literature DB >> 32640282

Intra-aortic balloon counterpulsation - Does it work?

Anne Freund1, Steffen Desch2, Holger Thiele3.   

Abstract

The intra-aortic balloon pump (IABP) has been in routine use for various cardiovascular indications for 5 decades. However, its regular use has been increasingly questioned. The aim of IABP counterpulsation is to enhance coronary blood flow and to reduce afterload of the left ventricle. In-vivo studies, however, provided insight into how physiological responses might counteract the desired effects of the device. Large randomized trials did not show benefit of IABP in the main indications such as infarct-related cardiogenic shock, high-risk myocardial infarction without shock and elective high-risk percutaneous coronary intervention. As these results are reflected differently in international guidelines and the interpretation of the evidence is heterogeneous, the frequency of IABP use differs considerably by region. Current research efforts predominantly focus on other active mechanical circulatory support devices making evidence-based approaches for possible final IABP niches more difficult.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiogenic shock; Coronary artery bypass grafting; Decompensated heart failure; Intra-aortic balloon pump; Intra-aortic counterpulsation; Mechanical circulatory support; Myocardial infarction; Percutaneous coronary intervention

Mesh:

Year:  2020        PMID: 32640282     DOI: 10.1016/j.pcad.2020.07.001

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  2 in total

1.  Statistical Analysis of IABP-Surgery Data with the Co-use of Anticoagulants, Pulse of Dorsalis Pedis Artery, D-Dimer Data, and Coagulation Function.

Authors:  Huali Chen; Zhoumin Shen; Yan Zhang; Zhaofen Zheng; Lihua Li; Xinyi Tian; Jianqiang Peng; Xi Peng; Yi Zhou
Journal:  Front Surg       Date:  2022-05-16

Review 2.  Cardiac Surgery in Advanced Heart Failure.

Authors:  Roger Hullin; Philippe Meyer; Patrick Yerly; Matthias Kirsch
Journal:  J Clin Med       Date:  2022-01-31       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.